CytoMed Therapeutics' ANGELICA Trial Receives Approval for Phase I Study in Advanced Cancers
• CytoMed Therapeutics has received full approval for its Phase I ANGELICA trial, evaluating allogeneic CAR-T cell therapy in advanced cancers.
• The ANGELICA trial uses gamma delta T cells from healthy donors, potentially improving CAR-T cell quality and reducing production costs.
• The trial is co-supported by the Singapore Ministry of Health through the National Medical Research Council (NMRC) and involves collaboration with the National University Hospital (NUH).
• Part 2 of the ANGELICA trial will proceed with the recruitment of patients with advanced cancers resistant to standard therapy regimens.
© Copyright 2025. All Rights Reserved by MedPath